Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy that uses the body’s own immune system to fight cancer. CAR-T cells are engineered to recognize and attack cancer cells, and they have been shown to be effective in treating a variety of different types of cancer, including leukemia, lymphoma, and myeloma.
CAR-T therapy is a complex and expensive treatment, but it has the potential to offer long-term remission for patients with cancer who have not responded to other treatments. In 2017, the FDA approved the first CAR-T therapy for the treatment of leukemia, and since then, several other CAR-T therapies have been approved for the treatment of different types of cancer.
Here’s a roundup of STAT coverage on a promising avenue of health and science research, including side effects and costs.